Mechanism

How it works

CJC-1295 (without DAC), also known as Mod GRF 1-29, binds to GHRH receptors on somatotroph cells in the anterior pituitary, increasing cAMP signaling and priming GH synthesis and release. Ipamorelin acts as a selective ghrelin mimetic, binding to the GHS-R1a receptor and triggering a separate, complementary intracellular calcium-dependent signaling cascade to stimulate GH secretion. Because they act through distinct receptor pathways, co-administration produces a synergistic pulse of GH release that closely mimics the body's natural pulsatile GH secretion, without significantly suppressing endogenous somatostatin.

Reported in research

Benefits

Synergistic, amplified growth hormone pulses compared to either peptide alone
Improved body composition: increased lean muscle mass and reduced adipose tissue
Enhanced recovery from training, injury, and surgery via IGF-1-mediated tissue repair
Improved sleep quality, particularly slow-wave (deep) sleep, supporting systemic recovery
Anti-aging effects including improved skin elasticity, joint health, and collagen synthesis
Minimal impact on cortisol and prolactin compared to non-selective GHRPs such as GHRP-6

Context, not a prescription

Dosing

Typical range: 100–200 mcg of each peptide per injection, 1–3 times daily (most commonly before bed) (Subcutaneous, Intramuscular)
Cycle length: 8–12 weeks, followed by 4–8 weeks off
Half-life: CJC-1295 no DAC: ~30 minutes; Ipamorelin: ~2 hours

Safety

Side effects & contraindications

Possible side effects

Transient flushing, tingling, or warmth at the injection site
Water retention and mild edema, particularly in extremities
Headache shortly after injection (usually transient)
Mild fatigue or lethargy, especially early in a cycle
Increased hunger (less pronounced with Ipamorelin than with GHRP-6)
Potential for elevated blood glucose due to GH-mediated insulin resistance with prolonged high-dose use

Contraindications

Active malignancy or history of cancer (GH elevation may stimulate tumor growth)
Diabetic individuals or those with impaired glucose tolerance without medical supervision
Pregnancy or breastfeeding
Acromegaly or any condition involving excess GH secretion
Children and adolescents with open growth plates without specialist oversight

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Better, deeper sleep; feeling more recovered after workouts; gradual improvements in body composition (less fat, more defined muscle); improved skin quality; reduced joint soreness.

How it works

Imagine your pituitary gland is a vending machine for growth hormone. CJC-1295 is like inserting the coins (loading the machine and priming it), while Ipamorelin is like pressing the button to actually dispense the product. Using both at the same time means you get a full, satisfying delivery every time.

After injection, both peptides travel through your bloodstream to the pituitary gland at the base of your brain. Within 15–30 minutes, your pituitary releases a pulse of growth hormone. This GH then signals your liver to produce IGF-1, which is the main driver of muscle repair, fat burning, and tissue regeneration throughout the body.

What to expect

Most users notice improved sleep depth within the first 1–2 weeks. Physical changes like reduced bloating, minor fat loss, and improved recovery typically become noticeable around weeks 3–4.

Week 1: Adjustment phase — you may notice improved sleep depth and some mild water retention. Injection-site reactions are most common here.
Weeks 2–4: Sleep quality noticeably improves. Recovery from workouts feels faster. Early fat-loss and minor body composition shifts may begin.
Weeks 4–8: More visible body composition changes: reduced body fat, improved muscle definition, better skin tone, and enhanced joint comfort. Energy and mood may improve.

Good to know

Start with the lowest effective dose (100 mcg of each) and assess tolerance before increasing
Inject on an empty stomach or at least 2 hours after eating to maximize GH pulse
Use bacteriostatic water to reconstitute and always refrigerate after mixing
Rotate injection sites to minimize local irritation

Staying safe

Redness, itching, or a small lump at the injection site — usually goes away in an hour
Water retention or puffy-feeling hands and feet, especially in the first few weeks
Mild headache shortly after injecting
Feeling hungry around injection time

Avoid if you have:

Anyone with a history of cancer or active tumors
Pregnant or breastfeeding women
Diabetics or pre-diabetics without medical supervision
Anyone under 21 or with unresolved growth plate issues

Overview

Acute: GH pulse with downstream IGF-1 induction, lipolytic signaling in adipocytes (HSL activation), and enhanced protein synthesis in myocytes. Subacute (weeks 2–4): Elevated collagen synthesis, improved nitrogen retention, enhanced satellite cell activation in skeletal muscle, and measurable improvements in sleep stage architecture. Chronic (weeks 4–12): Reduction in visceral adipose tissue, increases in lean body mass, improved bone mineral density signaling, enhanced skin dermal thickness via IGF-1-stimulated fibroblast activity.

How it works

The pituitary somatotroph can be modeled as a factory with two independent production triggers. GHRH-R activation (via CJC-1295) is analogous to engaging the factory's primary assembly line through increased energy supply (cAMP/PKA), while GHS-R1a activation (via Ipamorelin) is like activating the rapid-deployment conveyor belt via a separate calcium-mediated hydraulic system. Running both simultaneously maximizes throughput beyond what either line could achieve alone — a true receptor-level synergy.

Following subcutaneous administration, both peptides are absorbed through the interstitial fluid into systemic circulation. CJC-1295 no DAC reaches peak plasma concentration within 15–30 minutes with a half-life of ~30 minutes, making dosing timing critical for aligning with natural GH pulse windows. Ipamorelin has a slightly longer half-life of ~2 hours. The resulting GH pulse elevates systemic IGF-1 (primarily hepatic origin) within 2–6 hours post-injection, with IGF-1 elevation persisting for 12–24 hours following repeated dosing protocols. Unlike exogenous HGH, this approach preserves pulsatile secretion, which is important for avoiding IGF-1 receptor desensitization and maintaining physiological GH axis feedback integrity via somatostatin counter-regulation.

Onset & timeline

Pharmacodynamic GH elevation is detectable within 15–30 minutes post-injection by serum assay. Subjective sleep architecture improvement (increased slow-wave sleep) is typically reported within 5–10 days. Measurable IGF-1 baseline elevation occurs after 2–4 weeks of consistent twice-daily dosing. Statistically significant body composition changes (via DEXA) typically require 8–12 weeks at therapeutic dosing.

Days 1–3: Acute GH pulses are detectable pharmacodynamically. Transient local injection reactions most common in this phase. No measurable IGF-1 baseline shift yet.
Weeks 1–2: Cumulative GH pulses begin to elevate baseline IGF-1. Slow-wave sleep architecture improvement measurable via polysomnography. Mild water retention may peak and begin to resolve.
Weeks 2–8: Progressive lean mass accretion via IGF-1-mediated mTORC1 activation and satellite cell recruitment. Lipolysis in visceral and subcutaneous adipose tissue via GH-driven HSL upregulation. Collagen synthesis and joint tissue remodeling, tendon strengthening, and skin dermal matrix improvement become progressively apparent.

Getting the most from it

Time injections to coincide with natural GH pulse windows (immediately pre-sleep and optionally post-workout fasted state) to maximize physiological alignment
Cycle 8–12 weeks on, 4–8 weeks off to prevent GHS-R1a downregulation and maintain pituitary sensitivity
Monitor fasting IGF-1 levels at baseline and at 6–8 weeks to gauge hormonal response and adjust dosing
Avoid eating 2 hours pre-injection — somatostatin released postprandially and insulin spikes blunt GH pulse amplitude by up to 50%

Common side effects

Transient injection-site erythema and induration (~15–20% of users), resolving within 1–2 hours
Transient water retention due to GH-mediated renal sodium reabsorption, particularly in the first 2–3 weeks
Mild insulin resistance with twice-daily high-dose protocols — monitor fasting glucose if predisposed

Mechanism of action

CJC-1295 without DAC (Mod GRF 1-29) is a truncated, stabilized analogue of endogenous GHRH(1-44), retaining the first 29 amino acids required for receptor binding with substitutions at positions 2, 8, 15, and 27 to resist dipeptidyl peptidase-IV (DPP-IV) cleavage, extending its half-life from ~2 minutes to approximately 30 minutes. It binds the GHRH-R (a Gs-coupled GPCR) on anterior pituitary somatotrophs, activating adenylyl cyclase, elevating intracellular cAMP, and activating PKA, which promotes GH gene transcription and vesicular GH release. Ipamorelin is a pentapeptide GH secretagogue (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin receptor (GHS-R1a), a Gq/11-coupled GPCR that triggers IP3/DAG signaling, raises intracellular calcium via IP3-mediated ER release and voltage-gated calcium channel activation, and drives GH exocytosis. Co-administration exploits both cAMP/PKA and calcium signaling cascades simultaneously, producing a synergistic amplification of GH pulsatility. Critically, Ipamorelin exhibits high GHS-R1a selectivity with minimal cross-reactivity at ACTH or prolactin-releasing receptors, resulting in a clean GH pulse without the cortisol/prolactin elevation seen with GHRP-2 or GHRP-6.

Following subcutaneous administration, both peptides are absorbed through the interstitial fluid into systemic circulation. CJC-1295 no DAC reaches peak plasma concentration within 15–30 minutes with a half-life of ~30 minutes, making dosing timing critical for aligning with natural GH pulse windows. Ipamorelin has a slightly longer half-life of ~2 hours. The resulting GH pulse elevates systemic IGF-1 (primarily hepatic origin) within 2–6 hours post-injection, with IGF-1 elevation persisting for 12–24 hours following repeated dosing protocols. Unlike exogenous HGH, this approach preserves pulsatile secretion, which is important for avoiding IGF-1 receptor desensitization and maintaining physiological GH axis feedback integrity via somatostatin counter-regulation.

Pharmacodynamics

Pharmacodynamic GH elevation is detectable within 15–30 minutes post-injection by serum assay. Subjective sleep architecture improvement (increased slow-wave sleep) is typically reported within 5–10 days. Measurable IGF-1 baseline elevation occurs after 2–4 weeks of consistent twice-daily dosing. Statistically significant body composition changes (via DEXA) typically require 8–12 weeks at therapeutic dosing.

Acute: GH pulse with downstream IGF-1 induction, lipolytic signaling in adipocytes (HSL activation), and enhanced protein synthesis in myocytes. Subacute (weeks 2–4): Elevated collagen synthesis, improved nitrogen retention, enhanced satellite cell activation in skeletal muscle, and measurable improvements in sleep stage architecture. Chronic (weeks 4–12): Reduction in visceral adipose tissue, increases in lean body mass, improved bone mineral density signaling, enhanced skin dermal thickness via IGF-1-stimulated fibroblast activity.

Timeline

Days 1–3: Acute GH pulses are detectable pharmacodynamically. Transient local injection reactions most common in this phase. No measurable IGF-1 baseline shift yet.
Weeks 1–2: Cumulative GH pulses begin to elevate baseline IGF-1. Slow-wave sleep architecture improvement measurable via polysomnography. Mild water retention may peak and begin to resolve.
Weeks 2–8: Progressive lean mass accretion via IGF-1-mediated mTORC1 activation and satellite cell recruitment. Lipolysis in visceral and subcutaneous adipose tissue via GH-driven HSL upregulation. Collagen synthesis and joint tissue remodeling, tendon strengthening, and skin dermal matrix improvement become progressively apparent.

Comparisons

CJC-1295 No DAC + Ipamorelin — effectiveness High, safety Good, cost $$, Medium to use
CJC-1295 with DAC — effectiveness High, safety Moderate, cost $$, High to use
Tesamorelin — effectiveness High, safety Good, cost $$$, Medium to use
Exogenous rhGH (Somatropin) — effectiveness Very High, safety Moderate, cost $$$$, Low to use

Adverse effects

Common:

Transient injection-site erythema and induration (~15–20% of users), resolving within 1–2 hours
Transient water retention due to GH-mediated renal sodium reabsorption, particularly in the first 2–3 weeks
Mild insulin resistance with twice-daily high-dose protocols — monitor fasting glucose if predisposed

Rare:

Carpal tunnel syndrome-like symptoms (<5% of users, dose-dependent) due to fluid retention in the carpal tunnel
Temporary GH axis desensitization with very high-frequency dosing (>3x/day), potentially suppressing natural pulsatility
Orthostatic hypotension immediately post-injection in sensitive individuals

Contraindications & risk mitigation

Contraindicated in:

Individuals with IGF-1-sensitive malignancies (prostate, breast, colorectal) — IGF-1 elevation may be mitogenic
Type 1 or Type 2 diabetics with poor glycemic control — GH-induced insulin resistance may destabilize glucose management
Individuals with pituitary tumors or hypopituitarism of unknown etiology
Patients on exogenous corticosteroids — GH axis interaction may alter cortisol metabolism

Time injections to coincide with natural GH pulse windows (immediately pre-sleep and optionally post-workout fasted state) to maximize physiological alignment
Cycle 8–12 weeks on, 4–8 weeks off to prevent GHS-R1a downregulation and maintain pituitary sensitivity
Monitor fasting IGF-1 levels at baseline and at 6–8 weeks to gauge hormonal response and adjust dosing
Avoid eating 2 hours pre-injection — somatostatin released postprandially and insulin spikes blunt GH pulse amplitude by up to 50%

Qué hace

Better, deeper sleep; feeling more recovered after workouts; gradual improvements in body composition (less fat, more defined muscle); improved skin quality; reduced joint soreness.

Cómo funciona

Imagine your pituitary gland is a vending machine for growth hormone. CJC-1295 is like inserting the coins (loading the machine and priming it), while Ipamorelin is like pressing the button to actually dispense the product. Using both at the same time means you get a full, satisfying delivery every time.

After injection, both peptides travel through your bloodstream to the pituitary gland at the base of your brain. Within 15–30 minutes, your pituitary releases a pulse of growth hormone. This GH then signals your liver to produce IGF-1, which is the main driver of muscle repair, fat burning, and tissue regeneration throughout the body.

Qué esperar

Most users notice improved sleep depth within the first 1–2 weeks. Physical changes like reduced bloating, minor fat loss, and improved recovery typically become noticeable around weeks 3–4.

Week 1: Adjustment phase — you may notice improved sleep depth and some mild water retention. Injection-site reactions are most common here.
Weeks 2–4: Sleep quality noticeably improves. Recovery from workouts feels faster. Early fat-loss and minor body composition shifts may begin.
Weeks 4–8: More visible body composition changes: reduced body fat, improved muscle definition, better skin tone, and enhanced joint comfort. Energy and mood may improve.

Bueno saber

Start with the lowest effective dose (100 mcg of each) and assess tolerance before increasing
Inject on an empty stomach or at least 2 hours after eating to maximize GH pulse
Use bacteriostatic water to reconstitute and always refrigerate after mixing
Rotate injection sites to minimize local irritation

Manteniéndose seguro

Redness, itching, or a small lump at the injection site — usually goes away in an hour
Water retention or puffy-feeling hands and feet, especially in the first few weeks
Mild headache shortly after injecting
Feeling hungry around injection time

Evitar si tienes:

Anyone with a history of cancer or active tumors
Pregnant or breastfeeding women
Diabetics or pre-diabetics without medical supervision
Anyone under 21 or with unresolved growth plate issues

Descripción general

Acute: GH pulse with downstream IGF-1 induction, lipolytic signaling in adipocytes (HSL activation), and enhanced protein synthesis in myocytes. Subacute (weeks 2–4): Elevated collagen synthesis, improved nitrogen retention, enhanced satellite cell activation in skeletal muscle, and measurable improvements in sleep stage architecture. Chronic (weeks 4–12): Reduction in visceral adipose tissue, increases in lean body mass, improved bone mineral density signaling, enhanced skin dermal thickness via IGF-1-stimulated fibroblast activity.

Cómo funciona

The pituitary somatotroph can be modeled as a factory with two independent production triggers. GHRH-R activation (via CJC-1295) is analogous to engaging the factory's primary assembly line through increased energy supply (cAMP/PKA), while GHS-R1a activation (via Ipamorelin) is like activating the rapid-deployment conveyor belt via a separate calcium-mediated hydraulic system. Running both simultaneously maximizes throughput beyond what either line could achieve alone — a true receptor-level synergy.

Following subcutaneous administration, both peptides are absorbed through the interstitial fluid into systemic circulation. CJC-1295 no DAC reaches peak plasma concentration within 15–30 minutes with a half-life of ~30 minutes, making dosing timing critical for aligning with natural GH pulse windows. Ipamorelin has a slightly longer half-life of ~2 hours. The resulting GH pulse elevates systemic IGF-1 (primarily hepatic origin) within 2–6 hours post-injection, with IGF-1 elevation persisting for 12–24 hours following repeated dosing protocols. Unlike exogenous HGH, this approach preserves pulsatile secretion, which is important for avoiding IGF-1 receptor desensitization and maintaining physiological GH axis feedback integrity via somatostatin counter-regulation.

Inicio y cronología

Pharmacodynamic GH elevation is detectable within 15–30 minutes post-injection by serum assay. Subjective sleep architecture improvement (increased slow-wave sleep) is typically reported within 5–10 days. Measurable IGF-1 baseline elevation occurs after 2–4 weeks of consistent twice-daily dosing. Statistically significant body composition changes (via DEXA) typically require 8–12 weeks at therapeutic dosing.

Days 1–3: Acute GH pulses are detectable pharmacodynamically. Transient local injection reactions most common in this phase. No measurable IGF-1 baseline shift yet.
Weeks 1–2: Cumulative GH pulses begin to elevate baseline IGF-1. Slow-wave sleep architecture improvement measurable via polysomnography. Mild water retention may peak and begin to resolve.
Weeks 2–8: Progressive lean mass accretion via IGF-1-mediated mTORC1 activation and satellite cell recruitment. Lipolysis in visceral and subcutaneous adipose tissue via GH-driven HSL upregulation. Collagen synthesis and joint tissue remodeling, tendon strengthening, and skin dermal matrix improvement become progressively apparent.

Cómo aprovecharlo al máximo

Time injections to coincide with natural GH pulse windows (immediately pre-sleep and optionally post-workout fasted state) to maximize physiological alignment
Cycle 8–12 weeks on, 4–8 weeks off to prevent GHS-R1a downregulation and maintain pituitary sensitivity
Monitor fasting IGF-1 levels at baseline and at 6–8 weeks to gauge hormonal response and adjust dosing
Avoid eating 2 hours pre-injection — somatostatin released postprandially and insulin spikes blunt GH pulse amplitude by up to 50%

Efectos secundarios comunes

Transient injection-site erythema and induration (~15–20% of users), resolving within 1–2 hours
Transient water retention due to GH-mediated renal sodium reabsorption, particularly in the first 2–3 weeks
Mild insulin resistance with twice-daily high-dose protocols — monitor fasting glucose if predisposed

Mecanismo de acción

CJC-1295 without DAC (Mod GRF 1-29) is a truncated, stabilized analogue of endogenous GHRH(1-44), retaining the first 29 amino acids required for receptor binding with substitutions at positions 2, 8, 15, and 27 to resist dipeptidyl peptidase-IV (DPP-IV) cleavage, extending its half-life from ~2 minutes to approximately 30 minutes. It binds the GHRH-R (a Gs-coupled GPCR) on anterior pituitary somatotrophs, activating adenylyl cyclase, elevating intracellular cAMP, and activating PKA, which promotes GH gene transcription and vesicular GH release. Ipamorelin is a pentapeptide GH secretagogue (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin receptor (GHS-R1a), a Gq/11-coupled GPCR that triggers IP3/DAG signaling, raises intracellular calcium via IP3-mediated ER release and voltage-gated calcium channel activation, and drives GH exocytosis. Co-administration exploits both cAMP/PKA and calcium signaling cascades simultaneously, producing a synergistic amplification of GH pulsatility. Critically, Ipamorelin exhibits high GHS-R1a selectivity with minimal cross-reactivity at ACTH or prolactin-releasing receptors, resulting in a clean GH pulse without the cortisol/prolactin elevation seen with GHRP-2 or GHRP-6.

Following subcutaneous administration, both peptides are absorbed through the interstitial fluid into systemic circulation. CJC-1295 no DAC reaches peak plasma concentration within 15–30 minutes with a half-life of ~30 minutes, making dosing timing critical for aligning with natural GH pulse windows. Ipamorelin has a slightly longer half-life of ~2 hours. The resulting GH pulse elevates systemic IGF-1 (primarily hepatic origin) within 2–6 hours post-injection, with IGF-1 elevation persisting for 12–24 hours following repeated dosing protocols. Unlike exogenous HGH, this approach preserves pulsatile secretion, which is important for avoiding IGF-1 receptor desensitization and maintaining physiological GH axis feedback integrity via somatostatin counter-regulation.

Farmacodinamia

Pharmacodynamic GH elevation is detectable within 15–30 minutes post-injection by serum assay. Subjective sleep architecture improvement (increased slow-wave sleep) is typically reported within 5–10 days. Measurable IGF-1 baseline elevation occurs after 2–4 weeks of consistent twice-daily dosing. Statistically significant body composition changes (via DEXA) typically require 8–12 weeks at therapeutic dosing.

Acute: GH pulse with downstream IGF-1 induction, lipolytic signaling in adipocytes (HSL activation), and enhanced protein synthesis in myocytes. Subacute (weeks 2–4): Elevated collagen synthesis, improved nitrogen retention, enhanced satellite cell activation in skeletal muscle, and measurable improvements in sleep stage architecture. Chronic (weeks 4–12): Reduction in visceral adipose tissue, increases in lean body mass, improved bone mineral density signaling, enhanced skin dermal thickness via IGF-1-stimulated fibroblast activity.

Cronología

Days 1–3: Acute GH pulses are detectable pharmacodynamically. Transient local injection reactions most common in this phase. No measurable IGF-1 baseline shift yet.
Weeks 1–2: Cumulative GH pulses begin to elevate baseline IGF-1. Slow-wave sleep architecture improvement measurable via polysomnography. Mild water retention may peak and begin to resolve.
Weeks 2–8: Progressive lean mass accretion via IGF-1-mediated mTORC1 activation and satellite cell recruitment. Lipolysis in visceral and subcutaneous adipose tissue via GH-driven HSL upregulation. Collagen synthesis and joint tissue remodeling, tendon strengthening, and skin dermal matrix improvement become progressively apparent.

Comparaciones

CJC-1295 No DAC + Ipamorelin — efectividad High, seguridad Good, costo $$, Medium de usar
CJC-1295 with DAC — efectividad High, seguridad Moderate, costo $$, High de usar
Tesamorelin — efectividad High, seguridad Good, costo $$$, Medium de usar
Exogenous rhGH (Somatropin) — efectividad Very High, seguridad Moderate, costo $$$$, Low de usar

Efectos adversos

Comunes:

Transient injection-site erythema and induration (~15–20% of users), resolving within 1–2 hours
Transient water retention due to GH-mediated renal sodium reabsorption, particularly in the first 2–3 weeks
Mild insulin resistance with twice-daily high-dose protocols — monitor fasting glucose if predisposed

Raros:

Carpal tunnel syndrome-like symptoms (<5% of users, dose-dependent) due to fluid retention in the carpal tunnel
Temporary GH axis desensitization with very high-frequency dosing (>3x/day), potentially suppressing natural pulsatility
Orthostatic hypotension immediately post-injection in sensitive individuals

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with IGF-1-sensitive malignancies (prostate, breast, colorectal) — IGF-1 elevation may be mitogenic
Type 1 or Type 2 diabetics with poor glycemic control — GH-induced insulin resistance may destabilize glucose management
Individuals with pituitary tumors or hypopituitarism of unknown etiology
Patients on exogenous corticosteroids — GH axis interaction may alter cortisol metabolism

Time injections to coincide with natural GH pulse windows (immediately pre-sleep and optionally post-workout fasted state) to maximize physiological alignment
Cycle 8–12 weeks on, 4–8 weeks off to prevent GHS-R1a downregulation and maintain pituitary sensitivity
Monitor fasting IGF-1 levels at baseline and at 6–8 weeks to gauge hormonal response and adjust dosing
Avoid eating 2 hours pre-injection — somatostatin released postprandially and insulin spikes blunt GH pulse amplitude by up to 50%

Reference data

Specifications

Molecular formula: CJC-1295 no DAC: C₁₅₂H₂₅₂N₄₄O₄₂; Ipamorelin: C₃₈H₄₉N₉O₅
Molecular weight: CJC-1295 no DAC: ~3367.9 Da; Ipamorelin: ~711.9 Da
Half-life: CJC-1295 no DAC: ~30 minutes; Ipamorelin: ~2 hours
Route: Subcutaneous, Intramuscular
Cycle length: 8–12 weeks, followed by 4–8 weeks off
Storage: Store lyophilized (unreconstituted) powder at 2–8°C (refrigerated). After reconstitution with bacteriostatic water, store at 2–8°C and use within 28–30 days. Protect from light and avoid repeated freeze-thaw cycles. Stable at room temperature for short-term shipping (up to 72 hours).
Legal status: Research chemical in most jurisdictions; not approved for human use by FDA or EMA. Legal to purchase for laboratory/research purposes in many countries. Banned in competitive sports by WADA.

FAQ

Common questions

What is the pharmacological rationale for using CJC-1295 no DAC instead of CJC-1295 with DAC in this blend?

CJC-1295 with DAC (Drug Affinity Complex) incorporates a maleimidoproprionic acid linker that allows covalent binding to serum albumin, extending half-life to 6–8 days and producing chronic, blunted GH elevation. The no-DAC version produces discrete, pulsatile GH release more consistent with physiological GH secretion patterns. When blended with Ipamorelin for multiple daily injections, the no-DAC form is preferred to maintain pulsatility, avoid tachyphylaxis, and reduce risk of sustained GH elevation-associated side effects (insulin resistance, fluid retention). See Alba et al., 2006, J Clin Endocrinol Metab for comparative pharmacokinetics.

Does this combination suppress endogenous GHRH or somatostatin feedback?

Exogenous GHRH analogues do not directly suppress endogenous GHRH; rather, the resulting GH elevation triggers somatostatin release as negative feedback, which is a normal physiological response. Ipamorelin has been shown in preclinical studies to partially attenuate somatostatin tone at the hypothalamic level, which may be one reason for its synergistic effect with GHRH analogues. The pulsatile delivery pattern helps preserve GHS-R1a and GHRH-R sensitivity over time compared to continuous GH infusion.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for CJC-1295 (No DAC) + Ipamorelin 5mg Blend is rated as Limited human data. Limited human data is available.

1. Ipamorelin, the first selective growth hormone secretagogue (1998) — Eur J Endocrinol. 139(5):552-558. PMID: 9849822
2. CJC-1295, a long-acting growth hormone-releasing factor analogue (2006) — J Clin Endocrinol Metab. 91(3):799-805. Alba M et al.
3. Growth hormone secretagogues: history, mechanism of action, and clinical development (2012) — JPEN J Parenter Enteral Nutr. 36(1 Suppl):81S-95S
4. Ghrelin and the GH secretagogue receptor: from discovery to therapeutic development (2005) — Endocrine Reviews, 26(3):439-443

Explore

Often discussed alongside

BPC-157 · healing TB-500 · healing Tesamorelin · fat-loss IGF-1 LR3 · growth